ATEA PHARMACEUTICALS, INC.

(AVIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ATEA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

01/10/2022 | 08:13am EDT

Item 7.01 Regulation FD Disclosure

On January 10, 2022, in connection with its participation in the J.P. Morgan Healthcare Conference, Atea Pharmaceuticals, Inc. (the "Company") posted a corporate slide presentation in the "Investors" portion of its website at www.ateapharma.com. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

The information contained in Item 7.01 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit No.       Description

99.1                Corporate Slide Presentation of Atea Pharmaceuticals, Inc.
                  dated January 10, 2022

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ATEA PHARMACEUTICALS, INC.
05/10ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/10TRANSCRIPT : Atea Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/10Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business..
AQ
05/03Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on Ma..
AQ
03/294794 : Characterization of the Toxicity Profile of AT-527 (Bemnifosbuvir), a Novel Guanosi..
PU
03/294793 : Lack of Reproductive and Developmental Toxicity for AT-527 (Bemnifosbuvir), an Oral..
PU
03/28Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Soci..
AQ
03/02JPMorgan Adjusts Price Target for Atea Pharmaceuticals to $8 From $10, Maintains Neutra..
MT
03/01SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $9 from $10, Keeps Market Per..
MT
More news
Analyst Recommendations on ATEA PHARMACEUTICALS, INC.
More recommendations